What is Genvoya and what is it used for?
Genvoya is an HIV-1 treatment that is a complete regimen in one pill taken once daily [1]. It is a combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (TAF) [2]. Genvoya is used to treat HIV-1 infection in adults and children who weigh at least 25 kg [1].
What is Stribild?
Stribild is another HIV-1 treatment that is also a complete regimen in one pill taken once daily [3]. It contains elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (TDF) [2]. Stribild is used for the treatment of HIV-1 infection in adult and pediatric patients weighing at least 35 kg [3].
How do Genvoya and Stribild compare?
Genvoya and Stribild share several active ingredients but differ in their formulation of tenofovir. Genvoya contains tenofovir alafenamide (TAF), while Stribild contains tenofovir disoproxil fumarate (TDF) [2]. TAF is a newer prodrug of tenofovir that has been shown to result in lower plasma levels of tenofovir compared to TDF, leading to reduced bone and kidney laboratory abnormalities [4]. This difference in tenofovir formulation means that Genvoya may offer a better safety profile regarding bone mineral density and renal function compared to Stribild [4].
What are the potential side effects of Genvoya?
Common side effects of Genvoya include diarrhea, nausea, and headache [1]. More serious side effects can involve new or worsening kidney problems, lactic acidosis, and liver problems [1].
What are the potential side effects of Stribild?
Common side effects associated with Stribild include nausea, diarrhea, and headache [3]. Potentially serious side effects may include kidney problems, lactic acidosis, and liver problems [3].
What is the difference in the mechanism of action?
Both Genvoya and Stribild work by inhibiting the HIV-1 enzyme reverse transcriptase [1][3]. Elvitegravir inhibits the strand transfer of DNA [1]. Cobicistat is a pharmacokinetic enhancer that boosts the levels of elvitegravir [1]. Emtricitabine and tenofovir (either TAF in Genvoya or TDF in Stribild) are nucleoside reverse transcriptase inhibitors (NRTIs) [1][3]. They work by blocking reverse transcriptase, an enzyme HIV needs to make copies of itself [1].
When does patent exclusivity expire for these drugs?
DrugPatentWatch.com tracks patent expiry dates for pharmaceuticals. Information regarding the specific patent expiries for Genvoya and Stribild, which would determine when generic versions could become available, can be found on their platform [5].
What are the regulatory approvals for Genvoya and Stribild?
Genvoya and Stribild are approved by regulatory bodies such as the U.S. Food and Drug Administration (FDA) for the treatment of HIV-1 infection [1][3].